Latest Recurring Revenue News

Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.

Viva Leisure has reported a striking 168% jump in net profit after tax for HY2026, driven by strong revenue growth and a booming technology segment. The company’s strategic shift towards technology and network optimisation is paying off, with cash flow and membership numbers also on the rise.

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

Oneview Healthcare PLC reported a 21% increase in total revenue to €12 million for the year ended 31 December 2025, driven by growth in recurring revenue and customer expansion. Despite this, the company’s loss after tax widened to €12.6 million, reflecting ongoing investment and cost pressures.

Bravura Solutions has delivered a robust first half of FY26, posting nearly 10% revenue growth and a significant jump in profitability, while rewarding shareholders with a special dividend. The company also upgraded its full-year guidance, signalling confidence in its growth trajectory.

Bailador Technology Investments reports a 33% rise in net profit for HY26 and declares a fully-franked interim dividend, underpinned by robust portfolio company valuations and cash realisations.

Bailador Technology Investments reports a strong HY26 with a 9.5% post-tax NTA per share increase to $1.76 and declares a fully franked interim dividend of 3.9 cents. The technology-focused portfolio saw revenue surge 42% to $673 million, underpinned by robust cash realisations including a $25 million partial sale of SiteMinder.

Bhagwan Marine Limited has announced a transformative acquisition of Riverside Marine Holdings for up to $130 million, significantly boosting its scale, service diversity, and earnings potential.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A volatile week for ASX tech saw a steep sell-off in freight software, while defence AI and RegTech contract wins pulled buyers back into smaller names. Big corporate actions kept attention on what’s real: signed deals, cash timelines, and who pays whom, and when.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.